FDA clears Regeneron's RNAi myasthenia drug at $410,000 a year
Regeneron won FDA approval Wednesday for Livsayis, the first RNA interference drug cleared for an autoimmune disease, targeting generalized myasthenia gravis. The four-times-a-year shot lists at $410,000 for a year's supply. It's discovered by Alnylam and now faces Argenx and AstraZeneca in a crowded market.
- 2 sources report it: finance.yahoo.com, biopharmadive.com.
- The source published it on Nov 19, 2026 at 7:10 AM.
Nothing open. Every check passed.
Regeneron Pharmaceuticals picked up FDA approval Wednesday for Livsayis, a first-of-its-kind RNA interference therapy for generalized myasthenia gravis. The drug works by blocking production of C5, a protein tangled up in the errant immune attack behind the disease. It's cleared for adults with the most common form, the AChR antibody-positive kind.
The price tag is steep: a year's supply lists at $410,000, according to a Regeneron spokesperson. Regeneron is pitching convenience as the sell — Livsayis goes in as a subcutaneous injection four times a year. By contrast, AstraZeneca's newly approved Klygefa is dosed once a week.
Alnylam Pharmaceuticals discovered the drug and handed it to Regeneron in 2019 under a broad RNAi partnership. It arrived via a detour: Alnylam first aimed the compound, then called cemdisiran, at paroxysmal nocturnal hemoglobinuria, but it fell short as a monotherapy in early testing. That pushed a strategic pivot toward combination approaches and other inflammatory targets, myasthenia gravis among them.
Livsayis lands in a crowded room. It competes with a popular Argenx medicine and several AstraZeneca drugs that hit C5 in different ways. RBC Capital Markets analyst Brian Abrahams wrote that uptake is likely to be, quote, measured at first.
The approval matters beyond myasthenia gravis. Eight RNAi medicines had reached market before this one, most of them sold by Alnylam and aimed at rare diseases. Livsayis is the first RNAi drug approved for an autoimmune condition, a sign the technology is maturing alongside small molecules and antibodies.
For Regeneron, it's a chance to branch into immunology while it absorbs growing biosimilar competition for its flagship eye drug Eylea and braces for the eventual patent loss on anti-inflammatory blockbuster Dupixent. The company is also awaiting readouts on a new kind of blood thinner and an RNAi therapy for a common liver disease.
TopicsRegeneron Pharmaceuticals · Alnylam Pharmaceuticals · FDA · Livsayis · Argenx · AstraZeneca · Eylea · Dupixent
Written by AI from verified reporting.
More stories
- Health & science apnews.com 0 viewsA spacecraft's call takes 24 hours to cross 16 billion miles to Earth
- Health & science theguardian.com 1 viewNew Report Reveals Over 500 Moves To Roll Back Cancer Protections
- Health & science finance.yahoo.com 3 sources 1 viewHumacyte Files FDA Application to Add Dialysis Access as Second ATEV Use
- Health & science technologyreview.com 1 viewDonated liver survives seven weeks outside the body in Sydney record

